KLRS
Kalaris Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$3.90
−1.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 20.0K | 13.0K | — | — | — |
| Gross Profit | (20.0K) | (13.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 32.9M | 30.8M | 12.3M | 11.7M | 11.8M |
| SG&A Expense | 14.9M | 15.4M | 42.9M | 1.8M | 2.2M |
| General & Admin Expense | 7.0M | — | — | 1.8M | 2.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 47.7M | 46.1M | 55.3M | 13.5M | 14.0M |
| Cost and Expenses | 47.8M | 46.2M | 55.3M | 13.5M | 14.0M |
| Operating Income (EBIT) | (47.8M) | (46.2M) | (55.3M) | (13.5M) | (14.0M) |
| Non-Operating | |||||
| Interest Income | — | — | 5.5M | — | — |
| Interest Expense | — | 1.4M | — | 687.0K | 235.0K |
| Net Interest Income | — | (1.4M) | 5.5M | (687.0K) | (235.0K) |
| Other Non-Op Income/Expense | 3.5M | 2.7M | (3.5M) | (1.2M) | (1.5M) |
| Non-Operating Income (excl Interest) | (2.6M) | (4.2M) | 3.5M | 548.0K | 1.2M |
| EBT (Pre-Tax Income) | (44.3M) | (43.4M) | (58.8M) | (14.7M) | (15.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (44.3M) | (43.4M) | (58.8M) | (14.7M) | (15.5M) |
| Earnings from Cont. Ops | (44.3M) | (43.4M) | (58.8M) | (14.7M) | (15.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (44.3M) | (43.4M) | (58.8M) | (14.7M) | (15.5M) |
| Per Share | |||||
| Basic EPS | ($2.02) | ($2.85) | ($11.73) | ($42.09) | ($50.62) |
| Diluted EPS | ($2.02) | ($2.85) | ($11.73) | ($42.09) | ($50.62) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 23.8M | 15.3M | 5.0M | 4.5M | 3.3M |
| Diluted Shares Outstanding | 23.8M | 15.3M | 5.0M | 4.5M | 3.3M |
| Profitability Metrics | |||||
| EBITDA | (45.1M) | (42.0M) | (58.8M) | (14.0M) | (15.3M) |
| D&A | 30.0K | 13.0K | — | — | — |
| EBIT | (45.1M) | (42.0M) | (58.8M) | (14.0M) | (15.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026